Vallon Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 7.02 million compared to USD 9.3 million a year ago. Basic loss per share from continuing operations was USD 20.7 compared to USD 42.6 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.43 USD | -0.05% | -18.55% | -93.58% |
Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
2023 | Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
- Stock Market
- Equities
- GRI Stock
- News GRI BIOPAR
- Vallon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022